Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Google Secures Pentagon AI Deal for Classified Projects 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
CORALVILLE, Iowa, Feb. 18, 2016 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the RBC Capital Markets 2016 Healthcare Conference being held in New York, NY, February 23-24, 2016. Dr. Mickle will also present at the Cowen & Co. 36th Annual Health Care Conference 2016 being held in Boston, MA, March 7-9, 2016.
Details of KemPharm's presentations are as follows:
RBC Capital Markets 2016 Healthcare Conference
Date: Tuesday, February 23, 2016
Time: 3:35 PM (ET)
Location: The New York Palace Hotel in New York, NY
Cowen & Co. 36th Annual Health Care Conference 2016
Date: Monday, March 7, 2016
Time: 4:40 PM (ET)
Location: The Boston Marriott Copley Place in Boston, MA
The presentations will be webcast and available on the Investor Relations section of KemPharm's website at http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Jim Heins Cooney Waters Unlimited 212-886-2221 [email protected]
